Secondary Lymphedema
14
0
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
1 terminated out of 14 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
Imaging Biomarkers of Lymphatic Dysfunction
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment
Lymphaticovenous Anastomosis as Treatment for Lymphedema
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Supermicrosurgery for Breast Cancer Survivors With Lymphedema.
Complete Decongestive Therapy on Head and Neck Lymphedema
Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function
Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy
Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography
Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment
Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial
Physical Therapies in the Decongestive Treatment of Lymphedema